Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $27 to $30.
Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $27 to $30.